EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation

dc.contributor.authorAdamik, Juraj
dc.contributor.authorJin, Shunqian
dc.contributor.authorSun, Quanhong
dc.contributor.authorZhang, Peng
dc.contributor.authorWeiss, Kurt R.
dc.contributor.authorAnderson, Judith L.
dc.contributor.authorSilbermann, Rebecca
dc.contributor.authorRoodman, G. David
dc.contributor.authorGalson, Deborah L.
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2018-08-14T17:01:56Z
dc.date.available2018-08-14T17:01:56Z
dc.date.issued2017-04
dc.description.abstractIn multiple myeloma, osteolytic lesions rarely heal because of persistent suppressed osteoblast differentiation resulting in a high fracture risk. Herein, chromatin immunoprecipitation analyses reveal that multiple myeloma cells induce repressive epigenetic histone changes at the Runx2 locus that prevent osteoblast differentiation. The most pronounced multiple myeloma-induced changes were at the Runx2-P1 promoter, converting it from a poised bivalent state to a repressed state. Previously, it was observed that multiple myeloma induces the transcription repressor GFI1 in osteoblast precursors, which correlates with decreased Runx2 expression, thus prompting detailed characterization of the multiple myeloma and TNFα-dependent GFI1 response element within the Runx2-P1 promoter. Further analyses reveal that multiple myeloma-induced GFI1 binding to Runx2 in osteoblast precursors and recruitment of the histone modifiers HDAC1, LSD1, and EZH2 is required to establish and maintain Runx2 repression in osteogenic conditions. These GFI1-mediated repressive chromatin changes persist even after removal of multiple myeloma. Ectopic GFI1 is sufficient to bind to Runx2, recruit HDAC1 and EZH2, increase H3K27me3 on the gene, and prevent osteogenic induction of endogenous Runx2 expression. Gfi1 knockdown in MC4 cells blocked multiple myeloma-induced recruitment of HDAC1 and EZH2 to Runx2, acquisition of repressive chromatin architecture, and suppression of osteoblast differentiation. Importantly, inhibition of EZH2 or HDAC1 activity in pre-osteoblasts after multiple myeloma exposure in vitro or in osteoblast precursors from patients with multiple myeloma reversed the repressive chromatin architecture at Runx2 and rescued osteoblast differentiation.Implications: This study suggests that therapeutically targeting EZH2 or HDAC1 activity may reverse the profound multiple myeloma-induced osteoblast suppression and allow repair of the lytic lesions.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationAdamik, J., Jin, S., Sun, Q., Zhang, P., Weiss, K. R., Anderson, J. L., … Galson, D. L. (2017). EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation. Molecular Cancer Research : MCR, 15(4), 405–417. http://doi.org/10.1158/1541-7786.MCR-16-0242-Ten_US
dc.identifier.urihttps://hdl.handle.net/1805/17135
dc.language.isoen_USen_US
dc.publisherAmerican Association for Cancer Researchen_US
dc.relation.isversionof10.1158/1541-7786.MCR-16-0242-Ten_US
dc.relation.journalMolecular Cancer Researchen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectMultiple myelomaen_US
dc.subjectOsteoblast precursorsen_US
dc.subjectChromatinen_US
dc.subjectEpigeneticsen_US
dc.subjectGfi1en_US
dc.subjectRunx2en_US
dc.titleEZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiationen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
nihms875047.pdf
Size:
2.35 MB
Format:
Adobe Portable Document Format
Description:
Main article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: